These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22458547)

  • 1. Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling.
    Wager TT; Liras JL; Mente S; Trapa P
    Expert Opin Drug Metab Toxicol; 2012 May; 8(5):531-42. PubMed ID: 22458547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to optimize the brain availability of central nervous system drug candidates.
    Wager TT; Villalobos A; Verhoest PR; Hou X; Shaffer CL
    Expert Opin Drug Discov; 2011 Apr; 6(4):371-81. PubMed ID: 22646015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the prediction of drug disposition in the brain.
    Lanevskij K; Japertas P; Didziapetris R
    Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):473-86. PubMed ID: 23294027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New experimental models of the blood-brain barrier for CNS drug discovery.
    Kaisar MA; Sajja RK; Prasad S; Abhyankar VV; Liles T; Cucullo L
    Expert Opin Drug Discov; 2017 Jan; 12(1):89-103. PubMed ID: 27782770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.
    Stanimirovic DB; Bani-Yaghoub M; Perkins M; Haqqani AS
    Expert Opin Drug Discov; 2015 Feb; 10(2):141-55. PubMed ID: 25388782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico modeling on ADME properties of natural products: Classification models for blood-brain barrier permeability, its application to traditional Chinese medicine and in vitro experimental validation.
    Zhang X; Liu T; Fan X; Ai N
    J Mol Graph Model; 2017 Aug; 75():347-354. PubMed ID: 28628860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demystifying brain penetration in central nervous system drug discovery. Miniperspective.
    Di L; Rong H; Feng B
    J Med Chem; 2013 Jan; 56(1):2-12. PubMed ID: 23075026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restricting CNS penetration of drugs to minimise adverse events: role of drug transporters.
    Bagal S; Bungay P
    Drug Discov Today Technol; 2014 Jun; 12():e79-85. PubMed ID: 25027378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we predict blood brain barrier permeability of ligands using computational approaches?
    Kumar R; Sharma A; Tiwari RK
    Interdiscip Sci; 2013 Jun; 5(2):95-101. PubMed ID: 23740390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug transporters in the central nervous system.
    Stieger B; Gao B
    Clin Pharmacokinet; 2015 Mar; 54(3):225-42. PubMed ID: 25647629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADMET in silico modelling: towards prediction paradise?
    van de Waterbeemd H; Gifford E
    Nat Rev Drug Discov; 2003 Mar; 2(3):192-204. PubMed ID: 12612645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in brain penetration evaluation in drug discovery and development.
    Liu X; Chen C; Smith BJ
    J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
    Adenot M; Perriere N; Scherrmann JM; Lahana R
    Chemotherapy; 2007; 53(1):70-2. PubMed ID: 17202814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.
    Wager TT; Hou X; Verhoest PR; Villalobos A
    ACS Chem Neurosci; 2010 Jun; 1(6):435-49. PubMed ID: 22778837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery and in vitro models of the blood-brain barrier.
    Cucullo L; Aumayr B; Rapp E; Janigro D
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):89-99. PubMed ID: 15679176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development.
    Ohtsuki S; Terasaki T
    Pharm Res; 2007 Sep; 24(9):1745-58. PubMed ID: 17619998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular determinants of blood-brain barrier permeation.
    Geldenhuys WJ; Mohammad AS; Adkins CE; Lockman PR
    Ther Deliv; 2015; 6(8):961-71. PubMed ID: 26305616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a new conditionally immortalized cell line from human brain microvascular endothelial cells: a promising tool for human blood-brain barrier studies.
    Kamiichi A; Furihata T; Kishida S; Ohta Y; Saito K; Kawamatsu S; Chiba K
    Brain Res; 2012 Dec; 1488():113-22. PubMed ID: 23041702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates.
    Adenot M; Lahana R
    J Chem Inf Comput Sci; 2004; 44(1):239-48. PubMed ID: 14741033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.